ARTICLES BY THIS AUTHOR
- 11/14/2022
Case report: two-step TB testing
With the many students coming into his clinic for immunizations, Dr. Robert Dickson encounters an interesting TB skin test result. - 11/14/2022
Health Canada won't say how much new kids' pain medicine coming, where it's going
Chief Medical Adviser Dr. Supriya Sharma says the first signs of supply issues arose in April but it wasn't until August that companies warned their efforts to increase supplies were failing. - 11/13/2022
WEBINAR: The practical management of COPD in pharmacy
Coming up on Wednesday Nov, 23, 2022 at 12:00 p.m. EST, join pharmacist Mike Boivin as he leads a free webinar on COPD. - 11/13/2022
Has respect between doctors gone with the wind?
Specialists depend on referrals. If we, family doctors, says Dr. Jabir Jassam, acted together we could do something about disrespectful specialists. - 11/13/2022
Case report: A neck rash
A patient with a curious rash at Dr. Robert Dickson's clinic warrants a referral to the dermatologist. - 11/13/2022
New Democrats call for independent review of government's COVID-19 response
With the final federal public-health restrictions having been lifted in September, NDP health critic Don Davies said it's about time for the government to look back at whether appropriate actions were taken to manage the crisis. - 11/13/2022
Could recent advances present a genuine 'cure' for type 1 diabetes?
Highlights from the European Association for the Study of Diabetes congress in Stockholm. - 11/13/2022
Ontario's top doctor 'strongly' recommends masks, stops short of mandate
Dr. Kieran Moore made the recommendation Monday as part of an update on the pediatric respiratory virus season. - 11/13/2022
What is Mastodon? A social media expert explains how the ‘federated’ network works and why it won’t be a new Twitter
In the wake of Elon Musk’s noisy takeover of Twitter, people have been looking for alternatives to the increasingly toxic microblogging social media platform. - 11/12/2022
Follicular lymphoma: 6-year follow-up of the RELEVANCE trial
A recent study found the drug combination lenalidomide + rituximab is a durable, effective and safe alternative to the standard regimen combining rituximab and chemotherapy.